LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

28.55 0.35

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.92

Максимум

28.94

Ключови измерители
By Trading Economics
Приходи	-10M -113M
Продажби	1.2M 9.7M
Марж на печалбата	-1,162.384
Служители	510
EBITDA	-10M -107M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+71.29% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	422M 2.9B
Предишно отваряне	28.2
Предишно затваряне	28.55

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2.03.2026 г., 23:26 ч. UTC

Значими събития в новините

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2.03.2026 г., 22:21 ч. UTC

Пазарно говорене

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2.03.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2.03.2026 г., 22:06 ч. UTC

Пазарно говорене

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Energy & Utilities Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.03.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2.03.2026 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2.03.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 21:17 ч. UTC

Значими събития в новините

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2.03.2026 г., 20:44 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:43 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2.03.2026 г., 20:28 ч. UTC

Печалби

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2.03.2026 г., 20:25 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2.03.2026 г., 20:24 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2.03.2026 г., 20:05 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

71.29% нагоре

12-месечна прогноза

Среден 48.75 USD 71.29%

Висок 80 USD

Нисък 26 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.